Technical Data
N0017
NAG-1 (PTGF-b, PLAB, PDF, MIC-1)
Description:
NAG-1 is a TGF beta family member that is transcriptionally induced by p53. It induces growth arrest, inhibits tumorigenesis, and can be pro-apoptotic on colorectal cancer cells.

Applications:
Suitable for use in Immunohistochemistry and Western Blot. Other applications have not been tested.

Recommended Dilutions:
Immunohistochemistry: Reported to detect NAG-1 in formalin-fixed, Triton-X permeabilized, colon and lung paraffin sections. Antigen unmasking with sodium citrate required.
Western Blot: 2ug/ml detects the 35kD proform of NAG-1 from HCT-116 and LNCap cell lystaes.
Optimal dilutions to be determined by the researcher.

Recommended Secondary Antibodies:
I1904-39: IgG, X-Adsorbed (HRP) Pab Gt x Rb
I1904-40A: IgG, H&L, X-Adsorbed (HRP) Pab Gt x Rb
I1904-46Q: IgG, H&L (HRP) Pab Gt x Rb

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
50ug-20CBlue IceHumanRabbit
Concentration:
~1mg/ml
Immunogen:
Synthetic peptide corresponding to aa287-302, K-KTDTGVSLQTYDDLLA of human NAG-1, conjugated to Ovalbumin.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in 0.1M Tris-glycine, pH 7.4, 0.15M sodium chloride, 0.05% sodium azide, 30% glycerol.
Specificity:
Recognizes both pro- and secreted-forms of human NAG-1 at ~35kD and 10-15kD respectively. Does not crossreact with mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
US Biological Application References: 1. Park, J.Y. ,et al., J. Cancer Research and Clinical Oncology 134: 1029-1035 (2007). 2. Yang, H., et al., Mol. Cancer Therapy 2:1023-1029 (2003). General References: 1. Baek, S.J., et al., Mol. Pharmacol. 59: 901-908 (2001). 2 Bootcov, M.R., et al., PNAS USA 94: 11,514-11,519 (1997). 3. Paralkar, V.M., et al., J. Biol. Chem. 273: 13,760-13,767 (1998). 4. Lawton, L.N., et al., Gene 203: 17-26 (1997). 5. Chen et al., Journal of Pharmacology And Experimental Therapeutics 323:746-756 (2007).